Treatment of HER2-positive early (minimal) breast cancer
- Autores: Pesotsky R.S.1, Semiglazov V.F1, Tseluyko A.I1, Sokolova M.D1, Mortada V.V1, Tabagua T.T1, Krivorotko P.V1
-
Afiliações:
- N.N. Petrov National Medical Research Center of Oncology
- Edição: Volume 29, Nº 7 (2022)
- Páginas: 43-48
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321026
- DOI: https://doi.org/10.18565/pharmateca.2022.7.43-48
- ID: 321026
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
Roman Pesotsky
N.N. Petrov National Medical Research Center of Oncology
Email: ship-meback@gmail.com
Oncologist, Department of Breast Tumors St. Petersburg, Russia
V. Semiglazov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Tseluyko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
M. Sokolova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
V. Mortada
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
T. Tabagua
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
P. Krivorotko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Bibliografia
- Burstein, H.J., Curigliano, G., Thrlimann, B., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 ;32( 10): 1216-35. 10.1016/j.annonc.2021.06.023.
- Gianni L, Semiglazov Eiermann W., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014:640-47. doi: 10.1016/S1470-2045(14)70080-4.
- Gianni L, Semiglazov V., Manikhas G.M., et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (abstract 532). J Clin Oncol. 2007;25:532.
- Gianni L, Semiglazov Manikhas G.M., et al. Neoadjuvant trastuzumab plus doxorubicin, paclitaxel and CMF in locally advanced breast cancer (NOAH trial): Feasibility, safety and antitumor effects (abstract 144). ASC Breast Cancer Symposium, 2007.
- Gianni L, Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 201 0;3 75:377-84. Doi: 10.101 6/S0140- 6736(09)61964-4.
- Capelan M., Pugliano L., De Azambuja E., et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273-82. doi: 10.1093/annonc/ mds328.
- Gianni L., Pienkowski T., Im, Y.H., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’) (abstract S3-2). Presented at the 33rd annual San Antonio Breast Cancer Symposium. 2010. December, 8-12. San Antonio: Texas.
- Gianni L., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere') (abstract 1000). Presented at the San Antonio Breast Cancer Symposium. 2010. December, 8-12. San Antonio: Texas.
- Gianni L., et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7.
- Piccart M., et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clinical Oncol. 2021;39(13):1448-57. doi: 10.1200/JCO.20.01204.
- Ahn E.R., Vogel C.L. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012;131:371-83. doi: 10.1007/s10549-011-1781-y.
- Schneeweiss, A., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278- doi: 10.1093/annonc/mdt182.
- Perez E.A., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clinical Oncol. 2014;32(33):3744. doi: 10.1200/JCO.2014.55.5730.
- Pivot X., Romieu, G., Debled et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741-48. Doi: 10.1016/ S1470-2045(13)70225-0.
- Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15):1152-62. doi: 10.1200/JCO.2011.35.2245.
- Slamon D., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83. Doi: 10.1056/ NEJMoa0910383.
- Salgado R., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448-55. doi: 10.1001/jamaoncol.2015.0830.
- Sikov W.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triplenegative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13. doi: 10.1200/JCO.2014.57.0572.
- Loibl S., et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341-47. Doi: 10.1093/ annonc/mdy460.
- Gonzalez-Angulo A.M., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700. doi: 10.1200/JCO.2009.23.2025.
- Vaz-Luis I., et al. Outcomes by tumor subtype and treatment pattern in women with small, nodenegative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142. doi: 10.1200/JCO.2013.53.1608.
- Tolaney S.M., et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375-85. doi: 10.1200/JCO.20.03398.
- Harbeck N., et al. Primary analysis of KA1TL1N: A phase 111 study of trastuzumab emtansine (T-DM1)+ pertuzumab versus trastuzumab+pertuzumab+ taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). 2020. J Clin Oncol. doi: 10.1200/JCO.2020.38.15_suppl.500.
- Krop I.E., et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase IIIKAITLIN Study. J Clin Oncol. 2022;40(5):438-48. doi: 10.1200/JCO.21.00896.
- Hurvitz S.A., et al. Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. Lancet Oncol. 2019. doi: 10.1016/S1470-2045(17)30716-7.
- Von Minckwitz G., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-28. doi: 10.1056/NEJMoa1814017.
- Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8.